In an adult with a confirmed non‑union fracture and no contraindications, does low‑energy extracorporeal shockwave therapy facilitate bone healing?

Extracorporeal Shockwave Therapy for Non-Union Fractures

Yes, extracorporeal shockwave therapy (ESWT) should be considered as a first-line non-invasive treatment for confirmed non-union fractures, with evidence showing approximately 73% healing rates and superior safety compared to repeat surgical interventions.

The Evidence Base

The most compelling data comes from a 2019 systematic review 1 that analyzed 2 RCTs and 28 non-randomized studies, demonstrating:

• 73% union rate for established non-unions
• 86% union rate for delayed unions
• 81% union rate for post-surgical non-unions
• Only minor adverse events reported

A more recent 2026 systematic review 2 corroborates these findings, showing ESWT improves bone healing, reduces pain, and enhances functional recovery across multiple fracture types.

Why ESWT Works When Surgery Has Failed

The 2016 prospective trial 3 provides critical real-world evidence: 88.5% of tibial non-union patients achieved complete healing after ESWT, despite having undergone an average of 1.9 prior surgical interventions. This demonstrates ESWT's effectiveness even in treatment-resistant cases.

Critical timing factor: Patients who healed received ESWT at a mean of 355 days post-surgery versus 837 days for those who didn't heal (p<0.0001) 3. This means earlier application significantly improves outcomes—don't wait indefinitely after surgical failure.

Comparison to Other Modalities

Importantly, the 2017 BMJ guideline 4 explicitly mentions ESWT as a promising alternative when discussing future research directions for bone healing, specifically noting that "fracture research should focus on other interventions that have a greater probability to speed up healing, such as surgical application of adjuvant biomaterials or extracorporeal shock wave therapy." This stands in stark contrast to their strong recommendation against LIPUS (low-intensity pulsed ultrasound), which showed no benefit despite FDA approval.

Treatment Protocol

Based on the evidence:

• 3000-4000 impulses per session
• Energy flux density: 0.4 mJ/mm² (-6dB)
• Weekly sessions for approximately 23 weeks 3, 5
• Can be combined with rehabilitation exercises
• Non-invasive, well-tolerated, no significant adverse effects

Mechanism of Action

ESWT promotes healing through 6:

• Stimulation of osteoblast proliferation and differentiation
• Suppression of excessive osteoclast activity
• Induction of osteogenic responses at the cellular level
• Enhanced bone regeneration without surgical trauma

Clinical Decision Algorithm

For confirmed non-union fractures:

1. First 6-12 months post-injury/surgery: Consider ESWT as primary non-invasive option

   • Particularly if patient has surgical contraindications
   • Or if patient wishes to avoid repeat surgery

2. After failed initial surgery: Initiate ESWT within 12 months rather than waiting longer

   • Earlier application (around 355 days) shows significantly better outcomes than delayed application (>800 days)

3. High-risk features for non-union (from rib fracture data 7):

   • Bicortical displacement (20-fold increased risk)
   • Posterior location
   • Flail segments
   • Smoking status
   • Consider earlier ESWT intervention in these cases

Key Advantages Over Repeat Surgery

• No surgical complications (infection, hardware failure, anesthesia risks)
• Time-saving and cost-effective 3
• Similar efficacy: One RCT showed 71% ESWT healing vs 74% surgical healing 1
• Safer profile: Only minor adverse events versus surgical morbidity
• Outpatient procedure: No hospitalization required

Important Caveats

• Most studies have relatively small sample sizes and heterogeneous protocols 2
• The 2019 systematic review noted high risk of bias in 29 of 30 studies due to lack of randomization or control groups 1
• Standardized protocols still need refinement
• However, the consistency of positive results across multiple studies and anatomic locations (tibia, femur, scaphoid) strengthens the recommendation

Bottom Line

ESWT should be offered as first-line treatment for established non-unions before considering repeat surgery, given its 73% success rate, excellent safety profile, and non-invasive nature. The evidence is particularly strong for tibial non-unions but extends to other anatomic sites. Apply within the first year after surgical failure for optimal results—waiting beyond 12-18 months significantly reduces effectiveness.